RXRX Q2 2022 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+206.1% YoY

Gross Profit

-$7M-85.9% margin

Operating Income

-$66M-864.9% margin

Net Income

-$66M-856.7% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

+44.4%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$78M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$673M

Total Liabilities

$235M

Stockholders' Equity

$438M

Cash & Equivalents

$454M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$3M	+206.1%
Gross Profit	-$7M	$3M	-363.0%
Operating Income	-$66M	-$41M	-61.7%
Net Income	-$66M	-$43M	-51.1%

Revenue Segments

License and Service

$8M100%

Grant

$21,0000%